Revive Therapeutics Begins Laying Groundwork For Commercialization Of Bucillamine
Revive Therapeutics (CSE: RVV) this afternoon reported that it is in the process of pursuing a commercialization plan for the
Read more
Revive Therapeutics
Revive Therapeutics Partners With University of Health Sciences Antigua To Further Psychedelics Research
Revive Therapeutics (CSE: RVV) this morning announced that it has entered into a collaboration to further advance its psychedelic-assisted therapies.
Read more
Revive Therapeutics Looks To Bring Bucillamine To India
Revive Therapeutics (CSE: RVV) is looking to India. The company this morning indicated that it has entered into a memorandum
Read more
Revive Therapeutics Partners With UCSF To Study Bucillamine For Severe COVID-19
Revive Therapeutics (CSE: RVV) this morning had a major announcement, in that it has entered into a sponsored research agreement
Read more
Revive Therapeutics Applies For Orphan Drug Designation For Psilocybin
Revive Therapeutics (CSE: RVV) has filed for orphan drug designation with the US Food and Drug Administration. The filing relates
Read more
Revive Therapeutics Files For Patent On Oral Thin Film With Psilocybin
Revive Therapeutics (CSE: RVV) this morning announced that it has successfully completed research on an oral thin film delivery system
Read more
Revive Therapeutics Reports Successful Results Using Psilocybin To Treat Traumatic Brain Injury
Revive Therapeutics (CSE: RVV) this morning revealed that it has received positive results for a pre-clinical study that evaluated the
Read more
Revive Therapeutics To Expand Clinical Sites For Covid-19 Related Phase 3 Study
Revive Therapeutics (CSE: RVV) this morning provided an update on the status of its phase 3 clinical trial for the
Read more
PharmaTher, Revive, Complete Psilocybin Intellectual Property Transaction
PharmaTher (CSE: PHRM) has seen the completion of the sale of its psilocybin program to that of Revive Therapeutics (CSE:
Read more
Revive Therapeutics Closes $23.0 Million Bought Deal Financing
Revive Therapeutics (CSE: RVV) this morning announced the closing of its bought deal financing. Originally announced at a figure of
Read more